XML 44 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
ALLIANCES AND COLLABORATIONS (Otsuka) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Dec. 31, 2012
Jun. 30, 2013
Abilify [Member]
Jun. 30, 2012
Abilify [Member]
Jun. 30, 2013
Abilify [Member]
Jun. 30, 2012
Abilify [Member]
Jun. 30, 2012
Otsuka [Member]
Abilify [Member]
Jun. 30, 2012
Otsuka [Member]
Abilify [Member]
Jun. 30, 2012
Otsuka [Member]
Abilify [Member]
Upfront, milestone and other licensing payments [Member]
Jun. 30, 2012
Otsuka [Member]
Abilify [Member]
Upfront, milestone and other licensing payments [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Jun. 30, 2012
Otsuka [Member]
United States [Member]
Abilify [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Jun. 30, 2012
Otsuka [Member]
United States [Member]
Abilify [Member]
Dec. 31, 2015
Otsuka [Member]
United States [Member]
Abilify [Member]
Dec. 31, 2014
Otsuka [Member]
United States [Member]
Abilify [Member]
Dec. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Jan. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Dec. 31, 2012
Otsuka [Member]
United States [Member]
Abilify [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Up To 2 Point 7 Billion [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Between 2 Point 7 Billion And 3 Point 2 Billion [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Between 3 Point 2 Billion And 3 Point 7 Billion [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Between 3 Point 7 Billion And 4 Point 0 Billion [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Between 4 Point 0 Billion And 4 Point 2 Billion [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Over 4 Point 2 Billion [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Extension payment [Member]
Jun. 30, 2012
Otsuka [Member]
United States [Member]
Abilify [Member]
Extension payment [Member]
Jun. 30, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Extension payment [Member]
Jun. 30, 2012
Otsuka [Member]
United States [Member]
Abilify [Member]
Extension payment [Member]
Dec. 31, 2012
Otsuka [Member]
United States [Member]
Abilify [Member]
Extension payment [Member]
Apr. 30, 2009
Otsuka [Member]
United States [Member]
Abilify [Member]
Extension payment [Member]
Jun. 30, 2013
Otsuka [Member]
France, Germany, Spain, United Kingdom And Italy [Member]
Abilify [Member]
Jun. 30, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Jun. 30, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Jun. 30, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Jun. 30, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Jun. 30, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Operating expense up to $175 million [Member]
Jun. 30, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Operating expenses over $175 million [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales up to $400 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales up to $400 million [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales between $400 and $600 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales between $400 and $600 million [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales between $600 and $800 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales between $600 and $800 million [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual Net Sales Between $800 Million And $1 Billion [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual Net Sales Between $800 Million And $1 Billion [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual Sales In Excess Of $1 Billion [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual Sales In Excess Of $1 Billion [Member]
Alliances and Collaborations Statement [Line Items]                                                                                                      
The percentage of sales recognized by the Company when it is the principal in the customer sale. 100.00%   100.00%                                                                                                
Percentage of net sales recognized from collaboration                                       34.30%   51.50% 50.00% 20.00% 7.00% 2.00% 1.00% 20.00%             65.00%                                
Payment to extend term of commercialization agreement                                                                   $ 400                                  
Percentage of net sales payable to collaboration partner                           1.50%   1.50%                                                   65.00% 30.00% 12.00% 5.00% 3.00% 3.00% 2.00% 2.00% 1.00% 1.00%
Percentage of operating expense reimbursements from collaboration                                           30.00%                                   20.00% 1.00%                    
Payment made to Otsuka to assume full responsiblity for providing and funding all sales efforts.                                         27                                                            
Maximum reimbursement of operating expenses payable to a collaboration partner                                   8 56 82                                                              
Range of sales at which a given percentage will be paid to collaboration partner - minimum                                               2,700 3,200 3,700 4,000 4,200                               400   600   800   1,000  
Range of sales at which a given percentage will be paid to collaboration partner - maximum                                             2,700 3,200 3,700 4,000 4,200                             400   600   800   1,000      
Amount of operating expense at or below which collaboration partner will reimburse given percentage                                                                               175                      
Amount of operating expense over which collaboration partner will reimburse given percentage                                                                                 175                    
Abilify net sales, including amortization of extension payment 4,048 4,443 7,879 9,694   563 711 1,085 1,332 711 1,332                                                                                
Oncology Products collaboration fee expense                                                                       76 35 146 67                        
Royalty expense                           23 20 40 37                                                                    
Reimbursement of operating expenses to/(from) Otsuka 8 (19) 2 (32)                                                                                              
Amortization (income)/expense - extension payment                                                         17 17 33 33                                      
Amortization expense - upfront, milestone and other licensing payments     431 203               2 4                                                                            
Other assets - extension payment $ 1,104   $ 1,104   $ 904                                               $ 120   $ 120   $ 153